Comparative Pharmacology
Head-to-head clinical analysis: IONTOCAINE versus MARCAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IONTOCAINE versus MARCAINE HYDROCHLORIDE.
IONTOCAINE vs MARCAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iontocaine (lidocaine 2% and epinephrine 0.01%) combines a sodium channel blocker (lidocaine) to inhibit nerve impulse propagation, producing local anesthesia, with epinephrine causing vasoconstriction to reduce systemic absorption and prolong effect.
Bupivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, reversibly inhibiting nerve impulse propagation, particularly in sensory fibers.
IONTOCAINE is not a recognized drug. No standard dosing available.
Adults: 0.5% solution infiltrated up to 175 mg (35 mL) for minor procedures; for major procedures, up to 225 mg (45 mL) with epinephrine. Repeat doses at 3-hour intervals. Maximum dose 400 mg with epinephrine.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours; prolonged in renal impairment (up to 6-8 hours).
Terminal elimination half-life is approximately 2.5 to 3.5 hours in adults; may be prolonged in neonates (8-12 hours) or patients with hepatic impairment.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (15-20%); less than 10% fecal.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Metabolites are excreted renally, with a small amount in feces via biliary elimination.
Category C
Category C
Local Anesthetic
Local Anesthetic